Evidence map›Paper›PMID 39976231›Full record

ArticleeLife2025

Differences in HIV-1 reservoir size, landscape characteristics, and decay dynamics in acute and chronic treated HIV-1 Clade C infection.

Kavidha Reddy, Guinevere Q Lee, Nicole Reddy, Tatenda J B Chikowore, Kathy Baisley, Krista L Dong, Bruce D Walker, Xu G Yu, Mathias Lichterfeld, Thumbi Ndung'u

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. IBA-1Research square · 2026
    Article
  11. HIV reservoirs in lymphomagenesis: hidden driver in the era of viral suppression?Microbiology and molecular biology reviews : MMBR · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Post-intervention control in HIV immunotherapy trials.Current opinion in HIV and AIDS · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Kavidha ReddyAfrica Health Research Institute, Durban, South Africa.ORCID https://orcid.org/0000-0002-7024-0574
Guinevere Q LeeWeill Cornell Medical College, New York, United States.
Nicole ReddyAfrica Health Research Institute, Durban, South Africa.
Tatenda J B ChikoworeAfrica Health Research Institute, Durban, South Africa.
Kathy BaisleyAfrica Health Research Institute, Durban, South Africa.
Krista L DongRagon Institute of MGH, MIT and Harvard, Cambridge, United States.
Bruce D WalkerRagon Institute of MGH, MIT and Harvard, Cambridge, United States.
Xu G YuRagon Institute of MGH, MIT and Harvard, Cambridge, United States.
Mathias LichterfeldRagon Institute of MGH, MIT and Harvard, Cambridge, United States.ORCID https://orcid.org/0000-0001-9865-8350
Thumbi Ndung'uAfrica Health Research Institute, Durban, South Africa.ORCID https://orcid.org/0000-0003-2962-3992

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4M
Pathogenesis of Clade C HIV InfectionR37AI067073 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 2011 to 2020
$6.6M
Single-cell Proteogenomic profiling of HIV-1 reservoir cellsR01AI176579 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Mathias Lichterfeld · 2023 to 2026
$4.6M
Selection and Evolution of HIV-1 reservoir cells in blood and tissuesR01AI152979 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ESTES, JACOB D, LICHTERFELD, MATHIAS · 2020 to 2025
$3.8M
Immune selection of HIV-1 reservoir cells in human clinical trialsR01AI184094 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Mathias Lichterfeld · 2024 to 2026
$2.7M
Mentoring in patient-oriented research to finding a cure for HIV-1 infectionK24AI155233 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI LICHTERFELD, MATHIAS · 2021 to 2025
$958k
Bill and Melinda Gates Foundation OPP1066973Bill and Melinda Gates Foundation OPP1146433Gates Foundation INV-033558Gilead Sciences Grant ID #00406Gilead Sciences Inc Grant ID #19275International AIDS Vaccine Initiative UKZNRSA1001National Institute of Allergy and Infectious Diseases R37AI067073NIAID NIH HHS K24 AI155233NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI152979NIAID NIH HHS R01 AI176579NIAID NIH HHS R01 AI184094NIAID NIH HHS R37 AI067073Wellcome TrustWellcome Trust Del-22-007
6 · The paper itself

Abstract

Persisting HIV reservoir viruses in resting CD4 T cells and other cellular subsets are a barrier to cure efforts. Early antiretroviral therapy (ART) enables post-treatment viral control in some cases, but mechanisms remain unclear. We hypothesised that ART initiated before peak viremia impacts HIV-1 subtype C reservoirs. We studied 35 women at high risk of infection from Durban, South Africa, identified with hyperacute HIV by twice-weekly HIV-RNA testing. Participants included 11 starting ART at a median of 456 (297-1203) days post-onset of viremia (DPOV) and 24 at 1 (1-3) DPOV. Peripheral blood mononuclear cells (PBMCs) were used to measured total HIV-1 DNA by droplet digital PCR (ddPCR) and sequence viral reservoir genomes by full-length proviral sequencing (FLIP-seq). ART during hyperacute infection blunted peak viremia (p<0.0001), but contemporaneous total HIV-1 DNA did not differ (p=0.104). Over 1 year, a decline of total HIV-1 DNA was observed in early treated persons (p=0.0004), but not late treated. Among 697 viral genome sequences, the proviral genetic landscape differed between untreated, late treated, and early treated groups. Intact genomes after 1 year were higher in untreated (31%) versus late treated (14%) and early treated (0%). Treatment in both late and early infection caused more rapid decay of intact (13% and 51% per month) versus defective (2% and 35%) viral genomes. However, intact genomes persisted 1 year post chronic treatment but were undetectable with early ART. Early ART also reduced phylogenetic diversity of intact genomes and limited cytotoxic T lymphocyte immune escape variants in the reservoir. Overall, ART initiated in hyperacute HIV-1 subtype C infection did not impact reservoir seeding but was associated with rapid intact viral genome decay, reduced genetic complexity, and limited immune escape, which may accelerate reservoir clearance in combination with other interventional strategies.

Indexed as

Anti-Retroviral AgentsHIV-1HIV InfectionsAdultCD4-Positive T-LymphocytesDNA, ViralFemaleHumansLeukocytes, MononuclearProvirusesSouth AfricaViral LoadViremiaAnti-Retroviral AgentsDNA, ViralClade CHIV-1humaninfectious diseasemedicinemicrobiologyreservoirviral dynamics

Identifiers

PMID39976231
PMCPMC11841988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.